In this video, health-care analyst David Williamson discusses Biogen's latest drug up for FDA approval. The big biotech is on a roll lately: The FDA recently accepted applications for two hemophelia drugs and today came news of multiple sclerosis drug Plegridy. This is a longer-lasting, and therefore less-injected, version of the company's flagship product Avonex.

Watch and find out why this submission is important for expanding Avonex's sales and why it may help protect the franchise from its biggest threat, another recently approved Biogen MS drug.

David Williamson and The Motley Fool have no position in any stocks mentioned. Follow David on Twitter @MotleyDavid. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.